美国食品和药物管理局批准了杜皮森特用于慢性肺炎, FDA approves DUPIXENT for COPD, offering a new treatment targeting inflammatory pathways.

Regeneron和Sanofi的药物DUPIXENT经林业发展局批准,用于治疗慢性阻塞性肺病(COPD),标志着其第六批核准用途。 Regeneron and Sanofi's drug DUPIXENT has been approved by the FDA for treating Chronic Obstructive Pulmonary Disease (COPD), marking its sixth approved use. 与传统治疗不同,DUPIXENT针对特定发炎途径,表明严重恶化和肺功能改善减少了30%。 Unlike traditional treatments, DUPIXENT targets specific inflammatory pathways, showing a 30% reduction in severe exacerbations and improved lung function. 这一突破针对一小部分COPD患者, 提供了更有针对性的治疗选择. This breakthrough addresses a subset of COPD patients, offering a more targeted treatment option.